PatientsVille.com Logo

Herpes and Acyclovir

PatientsVille

Herpes Symptoms and Causes

Cold sores are caused by a contagious virus called Herpes simplex virus (HSV). There are two types of HSV. Type 1 usually causes oral Herpes, or cold sores. Type 1 Herpes virus infects more than half of the U.S. population by the time they reach their 20s. Type 2 usually affects the genital area.

Some people have no symptoms from the infection. But others develop painful and unsightly cold sores. Cold sores usually occur outside the mouth, on or around the lips. When they are inside the mouth, they are usually on the gums or the roof of the mouth. They are not the same as canker sores, which are not contagious.

There is no cure for cold sores. They normally go away on their own in a few weeks. Antiviral medicines can help them heal faster. They can also help to prevent cold sores in people who often get them. Other medicines can help with the pain and discomfort of the sores. These include ointments that numb the blisters, soften the crusts of the sores, or dry them out. Protecting your lips from the sun with sunblock lip balm can also help.

Check out the latest treatments for herpes

herpes treatment research studies

Acyclovir clinical trials, surveys and public health registries


Find Drug Side Effect reports



Acyclovir Side Effects

Renal Failure Acute (111)
Nausea (55)
Confusional State (53)
Neurotoxicity (52)
Blood Creatinine Increased (51)
Pyrexia (48)
Hallucination, Visual (38)
Herpes Zoster (38)
Vomiting (37)
Pain (37)
Fatigue (36)
Somnolence (36)
Renal Failure (35)
Diarrhoea (34)
Agitation (31)
Rash (31)
Renal Impairment (30)
Dyspnoea (30)
Haemodialysis (28)
Neutropenia (28)
Malaise (27)
Encephalopathy (27)
Febrile Neutropenia (27)
Dysarthria (26)
Hallucination (26)
Platelet Count Decreased (26)
Nephropathy Toxic (26)
Back Pain (24)
Alanine Aminotransferase Increased (23)
Insomnia (23)
Abdominal Pain (23)
Headache (22)
White Blood Cell Count Decreased (22)
Aphasia (22)
Pruritus (21)
Disorientation (20)
Hypertension (19)
Dizziness (19)
Pancytopenia (19)
Abdominal Pain Upper (19)
Coma (19)
Paraesthesia (19)
Pneumonia (18)
Sepsis (18)
Blood Pressure Increased (18)
Hepatotoxicity (17)
Anaemia (17)
Ataxia (17)
Hypotension (17)
Multi-organ Failure (17)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

How do u get cutaneous herpes

Wait, do you mean that there is a 65% chance of a false pos, or a 65% of a true pos?? Because then later you say that there's a 92% false pos for anything above 3.5? Do you mean to say the percentage is when it's a true pos?

Am on Dolcet, 3x a day for three weeks already due to herpes zoster pain. For fear of overdosage i stopped taking this, i shifted to Lyrica 75 mg. But the pain continues. Is it okay if I take Lyrica in the morning and dolcet in the afternoon?

Been on Orencia for 11 months, now have a skin infection on chest, herpes outbreak on ear taking antibiotics using steroid cream etc. Itchy skin most ofthetime and feeling tired, have noticed increase in fluid retention in lower l

Can Concerta cause shingles (herpes zoster)? I just started taking Concerta (36 mg) and I immediately developed shingles. My doctor swears it's a coincidence, but I can't help but wonder. I had chicken pox as a child, but I've never had shingles befo

Can the combanation of Lialda and Entocort cause herpes simplex

Four weeks after starting efudex to the scalp and left temple for early shin cancers developed left sided c3/c4 herpes Zoster

Herpes zoster eruption folllowed by prolonged pain while using rinderon ear drops.

How do u get cutaneous herpes

How long can one take zelitrex for as a prophlactic to prevent an outbreal of herpes 2? and at what dose?

I am on it for second day too. Only side effects I have had was diarrhea, slight headache, and for some reason I have a herpes blister on my hand, which is where the virus lies dormant (until now). I am hoping the blister will go away right after I g

I am taking rampihil 5 mg a day. I have a cough. Blurred vision. Dizzy. And i have now had 3 outbreaks of genital herpes since taking it in mid may 2011. What is your opinion?

Herpes Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study of the Safety of a Particular HERPES Vaccine in Adults With or Without HERPES Infection
Conditions: HERPES Genitalis;   HERPES Simplex Virus;   HERPES Simplex Virus Vaccines;   HSV Vaccines;   HERPESvirus Vaccines
Interventions: Biological: Injection;   Procedure: Blood Draw;   Procedure: Clinical evaluation of HERPES simplex diseases;   Procedure: Self swabbing for asymptomatic viral shedding;   Procedure: Collection of cervicovaginal secretions
Outcome Measure: Solicited injection site and systemic reactions days 0-7; unsolicited injection site reactions, systemic AEs, and SAEs entire study duration, anaphylaxis in first 30 minutes after vaccination
2 Recruiting Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' HERPES Zoster Vaccine GSK1437173A
Condition: HERPES Zoster
Interventions: Biological: HERPES Zoster vaccine GSK1437173A;   Biological: Placebo
Outcome Measures: Occurrence of confirmed HZ cases;   Duration of 'worst' HZ-associated pain;   Occurrence of confirmed HZ-associated complications;   Occurrence of Postherpetic Neuralgia (PHN);   Antigen-specific Antibody (Ab) concentrations in a sub-cohort of subjects;   Occurrence of solicited local and general symptoms;   Occurrence of unsolicited adverse events (AEs);   Occurrence of Serious Adverse Events (SAEs);   Occurrence of AEs of specific interest
3 Recruiting Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital HERPES
Condition: GENITAL HERPES
Interventions: Drug: Famciclovir;   Drug: Aciclovir
Outcome Measures: Efficacy will be evaluated by the proportion of subjects with non HERPES manifestation;   Safety will be evaluated by the Adverse events occurence
4 Recruiting Acupuncture in HERPES Zoster Neuralgia (ACUZoster)
Conditions: HERPES Zoster;   Postherpetic Neuralgia;   Pain
Interventions: Device: Sham-laser acupuncture;   Drug: gabapentine;   Procedure: Acupuncture
Outcome Measures: Alteration of pain intensity after treatment;   Quantitative sensory testing
5 Recruiting A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital HERPES
Condition: Genital HERPES
Intervention: Drug: PEG-Formulation
Outcome Measures: Change of number of genital HERPES recurrences during the treatment period as compared to the baseline period.;   The safety of the PEG-formulation via reporting of AEs.
6 Recruiting Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' HERPES Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Condition: HERPES Zoster
Interventions: Biological: HERPES Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Outcome Measures: HZ/su immunogenicity;   Pneumococcal vaccine immunogenicity;   Occurrence of solicited local and general symptoms;   Occurrence of unsolicited Adverse Events (AEs);   Occurrence of Serious Adverse Events (SAEs);   Occurrence of potential Immune Mediated Diseases (pIMDs)
7 Recruiting Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HERPES Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
Condition: HERPES Zoster
Interventions: Biological: HERPES Zoster vaccine GSK1437173A;   Drug: Placebo
Outcome Measures: Evaluation of anti-gE humoral immunogenicity, in all subjects, in terms of vaccine response.;   Occurrence of solicited local and general symptoms.;   Occurrence of unsolicited symptoms.;   Occurrence of serious adverse events (SAEs).;   Occurrence of adverse events of specific interest (AESIs).;   Evaluation of allograft function.;   Evaluation of anti-gE humoral immunogenicity in terms of antibody concentrations.;   gE-specific CD4+ T-cell mediated immunogenicity, in the CMI sub-cohort.;   Occurrence of SAEs.;   Occurrence of AESIs.
8 Recruiting Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' HERPES Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Condition: HERPES Zoster
Interventions: Biological: HERPES zoster vaccine (GSK 1437173A);   Drug: Placebo
Outcome Measures: Occurrence of solicited local and general symptoms;   Occurrence of unsolicited adverse events (AEs);   Occurrence of serious adverse events (SAEs);   Occurrence of AEs of specific interest;   Anti gE humoral immunogenicity in all vaccinated subjects excluding subjects with Non-Hodgkin B-cell Lymphoma and Chronic Lymphocytic Leukaemia;   Occurrence of SAEs;   Anti gE humoral immunogenicity in all vaccinated subjects excluding subjects with Non-Hodgkin B-cell Lymphoma;   Occurrence of confirmed HZ cases;   Anti-gE humoral immunogenicity in all vaccinated subjects;   gE-specific CD4+ T-cell-mediated immunogenicity response in the CMI sub-cohort;   Anti-gE humoral immunogenicity in subjects with confirmed HZ and matched controls
9 Recruiting Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HERPES Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Condition: HERPES Zoster
Interventions: Biological: HERPES Zoster vaccine GSK 1437173A;   Biological: Boostrix
Outcome Measures: HZ/su immunogenicity in terms of vaccine response;   Boostrix immunogenicity in terms of antibody concentrations;   HZ/su immunogenicity in terms of antibody concentrations;   Occurrence of solicited local and general symptoms;   Occurrence of unsolicited adverse events (AEs);   Occurrence of serious adverse events (SAEs);   Occurrence of potential Immune Mediated Diseases (pIMDs)
10 Recruiting Safety and Efficacy Trial of DNA Vaccines to Treat Genital HERPES in Adults
Condition: Genital HERPES Simplex Type 2
Interventions: Biological: VCL-HB01;   Biological: VCL-HM01;   Biological: PBS
Outcome Measures: Number of participants with adverse events;   Viral shedding rate change from baseline;   Genital lesion rate change from baseline;   HSV DNA copy numbers change from baseline;   Genital recurrence rate compared with placebo;   T-cell and/or antibody responses change from baseline
11 Not yet recruiting Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' HERPES Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
Condition: HERPES Zoster
Intervention: Biological: HERPES Zoster vaccine (GSK 1437173A)
Outcome Measures: Anti-gE humoral immunogenicity;   Occurrence of solicited local and general symptoms;   Occurrence of unsolicited symptoms;   Occurrence of Serious Adverse Events (SAEs);   Occurrence of AEs of specific interest
12 Recruiting Study to Estimate the Burden of HERPES Zoster and Postherpetic Neuralgia in Spain
Condition: HERPES Zoster
Intervention: Other: Data collection
Outcome Measures: Total number of HZ cases as recorded per participating practice, overall and within a specific age group and gender.;   Occurrence of PHN, i.e. persistence of HZ-related pain.;   Anamnestic information, clinical parameters and complications related to HZ.;   Direct medical, direct non-medical and indirect costs related to HZ.;   Pain assessment in HZ subjects.;   Quality of life assessment in HZ subjects;   Direct medical, direct non-medical and indirect costs related to PHN.;   Pain assessment in PHN subjects.;   Quality of life assessment in PHN subjects.
13 Recruiting A Study to Assess the Burden of HERPES Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above
Condition: HERPES Zoster
Intervention: Other: Data collection
Outcome Measures: Total number of HZ cases reported in the study area, overall and within a specific age-group and gender. The following age-groups will be considered: 60-69, 70-79 and ≥ 80 years of age.;   Occurrence of HZ-associated PHN pain, persisting between 90 and 270 days after the initial visit for this study.;   Occurrence of HZ-associated hospitalisations.;   Occurrence of HZ-associated any pain, persisting between 0 and 270 days after the initial visit for this study.;   Anamnestic information, clinical parameters and complications related to HZ.;   Direct medical, direct non-medical and indirect costs related to HZ.;   Quality of life (QoL) assessment in HZ subjects.;   Direct medical, direct non-medical and indirect costs related to PHN.;   QoL assessment in PHN subjects.;   Impact of the following factors on the development of PHN: - age, - gender, - concomitant disease, - current immunosuppressive therapy, - HZ severity at first consultation, - timing of initiation of treatment with antiviral agent etc.
14 Not yet recruiting A Multiple Ascending Dose-Finding Pharmacokinetic and Pharmacodynamic Study of a Novel Antiviral Drug in Infants With Neonatal HERPES Simplex Virus (HSV)
Condition: HERPES Simplex Virus
Interventions: Drug: Novel Antiviral Drug;   Drug: Placebo
Outcome Measures: Plasma pharmacokinetic parameters for a Novel Antiviral Drug, including AUC24, maximum serum concentration (Cmax), half-life (T1/2), CL/F, and time to maximum concentration (Tmax);   Clearance of HSV DNA from CSF by Day 4 of antiviral treatment of neonatal HSV disease;   The incidence of SAEs and AEs considered to be related to study treatment;   The incidence of grade 3-4 AEs and SAEs, with or without relationship to study treatment;   Intracellular pharmacokinetic parameters for the active diphosphate moiety of a Novel Antiviral Drug in peripheral blood mononuclear cells (PBMCs);   Correlation of a Novel Antiviral Drug plasma and intracellular concentrations with qualitative and quantitative HSV detection in cerebrospinal fluid and blood by PCR
15 Not yet recruiting Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With HERPES Zoster
Condition: HERPES Zoster
Interventions: Drug: Foscarnet Sodium;   Drug: Acyclovir
Outcome Measures: Effective rate;   Incidence of Postherpetic neuralgia;   number of participants with adverse event and serious adverse event
16 Recruiting The Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the HERPES Simplex Epithelial Keratitis
Condition: HERPES Simplex Keratitis
Intervention: Procedure: Corneal sampling
Outcome Measures: Result of the culture;   Time before positivity of the culture;   Viral load concentration
17 Unknown  Measuring HERPES Zoster and PHN Associated Burden of Illness and Health Care Utilization Costs in Thailand
Condition: HERPES Zoster
Intervention:
Outcome Measure:
18 Unknown  Comparison of Topical Antiviral Agents for Labial Cold Sores (HERPES Labialis)
Condition: Reccurent HERPES Labialis
Interventions: Drug: Acyclovir 5%;   Drug: Docosanol 10%;   Device: Superlysine gel
Outcome Measure: Reducing healing process and duration of cold sores using superlysin gel
19 Recruiting Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With HERPES Zoster
Condition: HERPES Zoster
Interventions: Drug: Famciclovir;   Drug: Aciclovir
Outcome Measures: For efficacy evaluation, a visual analogue scale (VAS) will be used to detect the improvement of symptoms;   Safety will be evaluated by the adverse events occurrences
20 Recruiting Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of HERPES Labialis
Condition: HERPES Labialis
Interventions: Drug: Squaric Acid solution;   Drug: Placebo solution
Outcome Measures: Number of days with lesions;   Number of days until first subject-reported recurrence.;   Number of adverse events reported